Nav Close

XEMPERIA SA, is a science-driven startup spin-off from the University of Fribourg, Switzerland. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.

Our Vision is to transform the future of cancer care through advanced blood testing.

Our Mission is to deliver innovative, accessible, and highly accurate blood tests for the early detection and monitoring of cancer-enhancing patient outcomes and reducing cancer-related mortality.

Our Solutions go beyond current methodologies that redefine whats possible in cancer diagnostics. Adaptable.

XEMPERIAs flagship solution is a blood test for early breast cancer detection to be offered yearly, to women at all ages as a first test in the breast cancer screening and diagnostic path.

News

07.11.2024 Xemperia wins over CHF 30'000 IFF Start-up Prize (startupticker.ch)
07.11.2024 Xemperia wins over CHF 30'000 IFF Start-up Prize (startupticker.ch)
27.06.2024 FIT Funding for Aspivix and Xemperia (startupticker.ch)

Milestones/News

28.02.2025 Second IP filed on the breast cancer blood test detectiongene signature
01.01.2025 Publication on DNA nanosensor for mutation detection
30.11.2024 GENOA clinical biomarker discovery study concluded
29.10.2024 Awarded Innosuisse Core Coaching
26.09.2024 Filed IP on RNA detection by DNA nanosensor
27.10.2022 Publication of DNA origami technology
10.10.2022 Filed IP on DNA origami nano technology
17.01.2021 Fist IP filed for the concept of the breast cancer detection blood test

Documents

Videos and Presentations


Xemperia Presentation Video

https://www.youtube.com/watch?v=KgzdORaNOG8